Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Deal Gives Xencor $150m Up Front, Up To $2.41bn In Milestone Fees

Executive Summary

Monrovia, California-based Xencor Inc.'s latest collaboration, which is worth $150m up front and up to $2.41bn in milestone fees from Novartis AG, shows how the company is growing up as its research and development pipeline matures.

Advertisement

Related Content

Immuno-Oncology 2.0 Roundtable: Scientific And Pricing Challenges Can't Slow New Therapies
Immuno-Oncology 2.0 Roundtable: Emerging Players Eye Crowded Field
Biopharma Quarterly Dealmaking Statistics, Q2 2016
Novartis Oncology Strategy: Focus On The Microenvironment
Amgen Bets $45m Plus Up To $1.7bn On Xencor's Bi-Specifics
BioNotebook: Ten deals and a breakup; Gilead/Ono, Vernalis/Novartis, Sorrento/NantWorks and more
BioNotebook: Xencor regains rights from Amgen; plus three other deals
BioNotebook: Ambit, Xencor, Soligenix, Ampio

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065526

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel